~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass.
uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA's Breakthrough Therapy, RMAT, Fast-Track, and Orphan Drug status with Accelerated Approval via cUHDRS. Similarly, QURE is building MRI-guided infusion centers, payer-access teams, and a US Center of Excellence network. All of these moves prove management's high confidence in AMT-130.
AMT to gain from increased investments by wireless carriers in 4G and 5G networks. Solid business fundamentals and strategic capital allocation are add-ons.
Infrastructure is essential to everyday life for most of civilization, which can provide stability and predictable cash flows. We are looking at two different closed-end funds that provide diversified exposure to the rather broad infrastructure space. Both invest in infrastructure and even include global weightings; however, the strategies employed still differ, which can make them complementary holdings.
BOSTON--(BUSINESS WIRE)--American Tower Corporation (NYSE: AMT) announced that its Board of Directors has declared a quarterly cash distribution of $1.70 per share on shares of the Company's common stock. The distribution is payable on July 11, 2025 to the stockholders of record at the close of business on June 13, 2025. About American Tower American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a po.
American Tower Corporation (NYSE:AMT ) Annual JPMorgan Global Technology, Media and Communications Conference May 13, 2025 10:50 AM ET Company Participants Steve Vondran - President and CEO Conference Call Participants Richard Cho - JPMorgan Richard Cho Hi. My name is Richard Cho.
American Tower benefits from strong secular trends in mobile data demand, 5G infrastructure expansion, and edge computing, driving robust top-and-bottom-line results. Despite recent sluggish stock performance, AMT's Q1 report highlights resilience with solid property revenues and AFFO growth, overcoming forex headwinds and the Sprint churn. AMT's dividend profile is impressive, with consistent growth and solid interest coverage, despite a modest yield compared to the sector median.
~ AMT-130 granted Breakthrough Therapy designation by FDA ~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT-130; regulatory update expected in the second quarter of 2025 ~ ~ AMT-260 clinical data from first patient to be presented at Epilepsy Therapies & Diagnostics Development Symposium on May 29, 2025 ~ ~ Cash, cash equivalents and current investment securities of approximately $409.0 million as of March 31, 2025 expected to fund operations into second half of 2027 ~ ~ uniQure to host inaugural earnings call at 8:30 a.m. ET ~ LEXINGTON, Mass.
AMT's Q1 results reflect a year-over-year rise in revenues, led by property and service operations segment revenues. Strong organic tenant billing growth aids results.
While the top- and bottom-line numbers for American Tower (AMT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
American Tower Corporation (NYSE:AMT ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Adam Smith - Senior Vice President, Investor Relations and FP&A Steve Vondran - President & Chief Executive Officer Rod Smith - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Matt Niknam - Deutsche Bank Jim Schneider - Goldman Sachs Ric Prentiss - Raymond James & Associates Michael Rollins - Citi Nick Del Deo - Moffett Nathanson Batya Levi - UBS Eric Luebchow - Wells Fargo Michael Funk - Bank of America Ben Swinburne - Morgan Stanley Jonathan Atkin - RBC Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the American Tower First Quarter 2025 Earnings Conference Call.
BOSTON--(BUSINESS WIRE)--American Tower Corporation (NYSE: AMT) today reported financial results for the quarter ended March 31, 2025. Steven Vondran, American Tower's Chief Executive Officer, stated, “The solid leasing trends we saw over the course of 2024 carried into the first quarter, with sustained demand across our global portfolio. In the U.S., accelerating broad-based mid-band deployments and the early indications of capacity-driven new site demand supported our highest quarter of servi.